Palliation and liver failure: Palliative medications dosage guidelines

Journal of Palliative Medicine

Volumn 10, Issue 3, 2007, Pages 677-685

  Rhee, Charles ^a   Broadbent, Andrew Mark ^a  

^a Braeside Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CELECOXIB; CHLORPROMAZINE; CLONAZEPAM; DEXTROPROPOXYPHENE; DIAZEPAM; FENTANYL; HYDROMORPHONE; IBUPROFEN; LIDOCAINE; LORAZEPAM; METHADONE; MEXILETINE; MIDAZOLAM; MORPHINE; NAPROXEN; OPIATE DERIVATIVE; OXAZEPAM; OXYCODONE; PARACETAMOL; PENTAZOCINE; PETHIDINE; PHENOBARBITAL; REMIFENTANIL; TEMAZEPAM; TRAMADOL; UNINDEXED DRUG;

AMNESIA; AUSTRALIA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; PALLIATIVE THERAPY; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

GUIDELINES; HUMANS; LIVER FAILURE; NEW SOUTH WALES; PALLIATIVE CARE;

EID: 34347374750     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.0246     Document Type: Review

References (44)

1. Garg RK: Anesthetic considerations in patients with hepatic failure. Int Anesthesiol Clin 2005;43:45-63.
2. Jones EA: Hepatocellular failure. In: Oxford Textbook of Medicine. Weatherall DJ, Ledingham JGG, Warrell DA (eds): Oxford: Oxford University Press, 1996, pp. 2100-2111.
3. Ghany M, Hoofnagle JH: Approach to the patients with liver disease. In: Harrison's Principles of Internal Medicine. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds): New York: McGraw-Hill, 2005.
4. Bower M, Cox S: Endocrine and metabolic complications of advanced cancer. In: Oxford Textbook of Palliative Medicine. Doyle D, Hanks G, Cherny NI, Calman K (eds): Oxford: Oxford University Press, 2004, pp. 687-702.
5. Hoyampa AM Jr, Branch RA, Schenker S: The disposition and effects of sedatives and analgesics in liver disease. Ann Rev Med 1978;29:205-218.
6. Lewis GP, Jusko WJ: Pharmacokinetics of ampicillin in cirrhosis. Clin Pharmacol Ther 1975;18:475-484t.
7. Schenker S, Bergstrom RF, Wolen RL, Lemberger L: Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988;44:353-359.
8. Bernard SA: The interaction of medications used in palliative care. Hematol Oncol Clin North Am 2002;16: 641-655.
9. Bass NM, Williams RL: Guide to drug dosage in hepatic disease. Clin Pharmacokinet 1988;15:396-420.
10. Patwardhan RV, Johnson RF, Hoyumpa A Jr, Sheehan JJ, Desmond PV, Wilkinson GR, Branch RA, Schenker S: Normal metabolism of morphine in cirrhosis. Gastroenterology 1981;81:1006-1111.
11. Crotty B, Watson KJ, Desmond PV, Mashford ML, Wood LJ, Colman J, Dudley FJ: Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol 1989; 36:501-506.
12. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J: The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990;29:289-297.
13. Kotb HI, el-Kabsh MY, Emara SE, Fouad EA: Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. Br J Anaesth 1997;79: 804-806.
14. Tegeder I, Lotsch J, Geisslinger G: Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999;37: 17-40.
15. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L: Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997;61:655-661.
16. Haberer JP, Schoeffler P, Couderc E, Duvaldestin P: Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982;54:1267-1270.
17. Navapurkar VU, Archer S, Gupta SK, Muir KT, Frazer N, Park GR: Metabolism of remifentanil during liver transplantation. Br J Anaesth 1998;81:881-886.
18. Riordan SM, Williams R: Treatment of hepatic encephalopathy [see comment]. N Engl J Med 1997;337: 473-479.
19. Forrest JA, Adriaenssens P, Finlayson ND, Prescott LF: Paracetamol metabolism in chronic liver disease. Eur J Clin Pharmacol 1979;15:427-431.
20. Roberts MS, Rumble RH, Wanwimolruk S, Thomas D, Brooks PM: Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease. Eur J Clin Pharmacol 1983;25:253-261.
21. Juhl RP, Van Thiel DH, Dittert LW, Albert KS, Smith RB: Ibuprofen and sulindac kinetics in alcoholic liver disease. Clin Pharmacol Ther 1983;34:104-109.
22. Calvo MV, Dominguez-Gil A, Macias JG, Diez JL: Naproxen disposition in hepatic and biliary disorders. Int J Clin Pharmacol Ther Toxicol 1980;18:242-246.
23. Williams RL, Upton RA, Cello JP, Jones RM, Blitstein M, Kelly J, Nierenburg D: Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol 1984;27: 291-296.
24. Micromedex Health Series. Greenwood Village, CO: Thomson Micromedex, 2005.
25. Klotz U, Rapp T, Muller WA: Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol 1978;13:55-60.
26. Shull HJ, Wilkinson GR, Johnson R, Schenker S: Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976;84:420-425.
27. Kraus JW, Desmond PV, Marshall JP, Johnson RF, Schenker S, Wilkinson GR: Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 1978;24:411-419.
28. Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C: Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989;29:272-277.
29. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR: The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975;55:347-359.
30. Sonne J, Andreasen PB, Loft S, Dossing M, Andreasen F: Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology 1990;11: 951-956.
31. Ghabrial H, Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen KJ, Mashford ML: The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 1986;30:93-97.
32. Uribe M, Ballesteros A, Strauss R, Rosales J, Garza J, Villalobos A, Briones A, Garcia Ramos G: Successful administration of metoclopramide for the treatment of nausea in patients with advanced liver disease. A double-blind controlled trial. Gastroenterology 1985;88: 757-762.
33. Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ: Pharmacokinetics of ondansetron in patients with hepatic insuffi-ciency. J Clin Pharmacol 1996;36:206-215.
34. Acocella G, Bonollo L, Garimoldi M, Mainardi M, Tenconi LT, Nicolis FB: Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 1972;13: 47-53.
35. Verbeeck RK, Patwardhan RV, Villeneuve JP, Wilkinson GR, Branch RA: Furosemide disposition in cirrhosis. Clin Pharmacol Ther 1982;31:719-725.
36. Abshagen U, Rennekamp H, Luszpinski G: Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment. Eur J Clin Pharmacol 1977; 11:169-176.
37. Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ: Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981;30:353-362.
38. Pond SM, Tong T, Benowitz NL, Jacob P: Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver. Aust NZ J Med 1980;10:515-519.
39. Benson GD: Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983;33:95-101.
40. Maxwell JD, Carrella M, Parkes JD, Williams R, Mould GP, Curry SH: Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. Clin Sci 1972;43: 143-151.
41. Alvin J, McHorse T, Hoyumpa A, Bush MT, Schenker S: The effect of liver disease in man on the disposition of phenobarbital. J Pharmacol Exp Ther 1975;192: 224-235.
42. Dalhoff K, Almdal TP, Bjerrum K, Keiding S, Mengel H, Lund J: Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol 1991;41:351-354, 1991.
43. Madsbad S, Bjerregaard B, Henriksen JH, Juhl E, Kehlet H: Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis. Gut 1980;21:52-56.
44. Pickup ME: Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1979;4:111-128.